First GLP‑1 pill cleared by FDA
The FDA approved oral semaglutide as the first GLP‑1 pill for weight loss, giving patients an alternative to injectable GLP‑1 medicines. (ajmc.com) Analysts say the GLP‑1 wave is reshaping fitness and consumer services — gyms and premium providers are already positioning themselves as complementary to GLP‑1 use — and doctors recommend specific strength work to preserve muscle during rapid drug‑assisted weight loss. (businessinsider.com) (indianexpress.com)
Glucagon-like peptide-1 drugs copy a gut hormone that slows stomach emptying and cuts appetite. On December 22, 2025, the Food and Drug Administration approved Wegovy tablets, an oral semaglutide pill, for adults with obesity or overweight plus a weight-related condition. (fda.gov) The new approval gives Wegovy two forms in the United States: a weekly injection and a daily tablet. The tablet label also covers reducing major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. (accessdata.fda.gov) The approval rested on Novo Nordisk’s OASIS 4 trial, which enrolled 307 adults without diabetes. At 64 weeks, oral semaglutide patients lost 13.6% of body weight on average, versus 2.2% with placebo, and 76% lost at least 5% of body weight versus 31% on placebo. (ajmc.com) The pill arrives as drugmakers race to move obesity treatment beyond injections. The Food and Drug Administration approved a higher-dose Wegovy injection, called Wegovy HD at 7.2 milligrams, on March 19, 2026, under the agency’s Commissioner’s National Priority Voucher pilot. (fda.gov) The spread of these drugs is already changing businesses outside medicine. Business Insider reported on April 11, 2026, that users are spending on trainers, supplements, healthier food, and new wardrobes, while gyms and other premium services position themselves as add-ons to drug-assisted weight loss. (businessinsider.com) Fitness operators are building programs around that demand. Inspire360 said in a March 2026 industry report that 17 fitness clubs and 10 solution providers had taken concrete steps to serve members using glucagon-like peptide-1 drugs. (atfw.ca) Doctors are also warning that fast weight loss can shrink muscle along with fat. Mass General Brigham said in June 2025 that lean-mass loss happens with weight loss broadly, not only with glucagon-like peptide-1 drugs, and that exercise plus a high-protein diet can help preserve bone and muscle. (advances.massgeneral.org) A July 2025 comment in Nature Reviews Endocrinology said rapid weight loss with glucagon-like peptide-1 receptor agonists can come at the cost of skeletal muscle and called for treatment plans that prioritize muscle preservation. (nature.com) Wegovy tablets carry the same boxed warning semaglutide products already have for thyroid C-cell tumors seen in rodents, and the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The pill expands access, but the medical advice around it still centers on diet, activity, and close follow-up. (accessdata.fda.gov)
